Imaging Markers of High-Risk Plaque Phenotype for Predicting Post-PCI Outcomes

Imaging Markers of High-Risk Plaque Phenotype for Predicting Post-PCI Outcomes (IMPACT-PCI) Study: A Multicenter Cohort Study Based on Coronary CT Angiography

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07117084

Acronym

IMPACT-PCI

Enrollment

2000

Registered

2025-08-12

Start date

2021-01-01

Completion date

2025-12-31

Last updated

2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis of Coronary Artery, Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)

Brief summary

Despite the widespread use of stents, previous studies have shown that stent implantation mainly relieves symptoms but may not significantly improve long-term outcomes in patients with stable coronary artery disease. Identifying the types of plaques that are most likely to benefit from stenting is essential for improving personalized treatment. This study explores whether coronary computed tomography angiography (CCTA)-derived imaging biomarkers of coronary plaques are associated with increased risk of adverse outcomes after percutaneous coronary intervention (PCI). Around 2,000 patients who underwent CCTA followed by stent placement were included. Advanced software was used to quantify plaque inflammation and composition. Findings from this research may help guide personalized treatment strategies in patients undergoing PCI.

Interventions

DIAGNOSTIC_TESTCCTA-derived Plaque Quantification

Quantitative analysis of coronary plaque features based on coronary CT angiography using semi-automated software.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. patients aged 18 years or older; 2. patients who underwent clinically indicated PCI within 30 days following CCTA; 3. CCTA demonstrating the presence of coronary atherosclerotic plaque.

Exclusion criteria

1. patients whose PCI within 30 days after CCTA was performed on an emergency basis; 2. elevated cardiac troponin levels within the 3 months preceding PCI; 3. inadequate CCTA image quality; 4. balloon-only or mixed stent/balloon PCI strategies; 5. PCI for non-atherosclerotic lesions (e.g., in-stent restenosis, spontaneous coronary dissection); 6. history of coronary artery bypass grafting; 7. heart failure; 8. non-ischemic cardiomyopathy; 9. significant valvular heart disease; 10. refractory hypertension; 11. persistent atrial fibrillation.

Design outcomes

Primary

Measure	Time frame	Description
Major adverse cardiovascular events (MACE)	From the date of PCI until December 2024 (minimum 2-year follow-up)	Composite of cardiovascular death, non-fatal myocardial infarction, repeat revascularization, and hospitalization for unstable angina.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026